HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Largest Meta-Analysis Suggests Higher Omega-3 Doses For Heart Health

Executive Summary

Omega-3 supplementation results in 8% reduction in heart attack and coronary heart disease risk over a five-year period versus placebo, finds a meta-analysis in JAMA. Encompassing 120,000 patients, research updates recent meta-analyses with addition of three studies in past year, two casting doubt on heart health benefits of omega-3s.

You may also be interested in...



STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.

US Omega-3 Sales Expected To Grow Nearly 6% As Less ‘Mature’ Markets Accelerate

US and Europe led in 2019 sales of omega-3-fortified products worldwide, a market valued at $44bn that has extended beyond supplements and baby formulas to include foods, beverages and pet food, says GOED in report released 26 May. As the US market is ‘mature,’ its sales growth is expected at 5.8% in 2021, while sales of less mature markets such as Asia (excluding China) is anticipated to climb 12.6%.

US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish

Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel